Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

general volatile anaesthesia

PreclinicalSmall molecule

MMedical University of Bialystok

general volatile anaesthesia is one of 2 small molecule programs targeting General Anaesthesia. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

General AnaesthesiaCompleted

General AnaesthesiaPreclinical

Completed

Competition

Competitive Landscape

3 competitors in General Anaesthesia

#DrugCompanyPhaseTrials

General Anaesthesia

AAssistance Publique - Hôpitaux de Paris

general volatile anaesthesia

MMedical University of Bialystok

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

General Anaesthesia1 trial

Serum Tryptase Concentration During General Anaesthesia With Rocuronium

Completed·MMedical University of Bialystok·N/A·NCT04035707·126 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for general volatile anaesthesia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — general volatile anaesthesia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for general volatile anaesthesia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Bialystok company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMedical University of Bialystok

Related News